XML 17 R4.htm IDEA: XBRL DOCUMENT v3.25.2
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Operating expenses    
Research and development $ 51,964 $ 30,312
General and administrative 18,613 12,688
Total operating expenses 70,577 43,000
Other income, net 3,924 2,674
Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds 30,900 (76,211)
Loss before income taxes (35,753) (116,537)
Provision for income taxes (431) 0
Net loss and comprehensive loss (36,184) (116,537)
Common Stock [Member]    
Operating expenses    
Net loss and comprehensive loss $ (31,992) $ (91,987)
Basic earnings per share of common stock (As Restated) $ (0.66) $ (3.74)
Diluted earnings per share of common stock (As Restated) $ (0.66) $ (3.74)
Weighted-average common shares outstanding, basic (As Restated) 48,543,787 24,619,197
Weighted-average common shares outstanding, diluted (As Restated) 48,543,787 24,619,197
Series X and Series X1 Non Voting Convertible Preferred Stock [Member]    
Operating expenses    
Net loss and comprehensive loss $ (4,192) $ (24,550)
Basic earnings per share of common stock (As Restated) $ (36.61) $ (207.58)
Diluted earnings per share of common stock (As Restated) $ (36.61) $ (207.58)
Weighted-average common shares outstanding, basic (As Restated) 114,508 118,268
Weighted-average common shares outstanding, diluted (As Restated) 114,508 118,268